Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Do Incretins Play An Important Role In the Cardiovascular System?

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Chemotherapy Strategies for Metastatic PDAC
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?